AsiDNA Treatment Induces Cumulative Antitumor Efficacy with a Low Probability of Acquired Resistance
The Achilles heel of anticancer treatments is intrinsic or acquired resistance. Among many targeted therapies, the DNA repair inhibitors show limited efficacy due to rapid emergence of resistance. We examined evolution of cancer cells and tumors treated with AsiDNA, a new DNA repair inhibitor target...
Main Authors: | Wael Jdey, Maria Kozlak, Sergey Alekseev, Sylvain Thierry, Pauline Lascaux, Pierre-Marie Girard, Françoise Bono, Marie Dutreix |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-09-01
|
Series: | Neoplasia: An International Journal for Oncology Research |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1476558619302131 |
Similar Items
-
Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors
by: Nirmitha I. Herath, et al.
Published: (2019-11-01) -
Evolution of tumor cells during AsiDNA treatment results in energy exhaustion, decrease in responsiveness to signal, and higher sensitivity to the drug
by: Pierre‐Marie Girard, et al.
Published: (2020-08-01) -
Inhibition of DNA Repair by Inappropriate Activation of ATM, PARP, and DNA-PK with the Drug Agonist AsiDNA
by: Nathalie Berthault, et al.
Published: (2022-07-01) -
A Preclinical Study Combining the DNA Repair Inhibitor Dbait with Radiotherapy for the Treatment of Melanoma
by: Julian Biau, et al.
Published: (2014-10-01) -
Asymptotic Properties for Cumulative Probability Models for Continuous Outcomes
by: Chun Li, et al.
Published: (2023-12-01)